Eloxx Pharmaceuticals Inc (ELOX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [OTC US]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
| 12-2013 | 09-2013 | 06-2013 | 03-2013 | 12-2012 | |
| Cash Flows From Operating Activities | |||||
| Net Income | -3,404 | -1,784 | -6,120 | -4,192 | -3,350 |
| Depreciation Amortization | 153 | 75 | 290 | 202 | 130 |
| Accounts payable and accrued liabilities | -160 | 367 | N/A | 92 | N/A |
| Other Working Capital | 506 | 729 | -210 | -32 | 1,710 |
| Other Operating Activity | 812 | -57 | 2,140 | 973 | 310 |
| Operating Cash Flow | $-2,092 | $-671 | $-3,900 | $-2,956 | $-1,200 |
| Cash Flows From Investing Activities | |||||
| PPE Investments | N/A | N/A | -1 | -1 | -1 |
| Purchase Sale Intangibles | -253 | -143 | N/A | -394 | N/A |
| Other Investing Activity | -253 | -143 | -519 | -394 | -249 |
| Investing Cash Flow | $-253 | $-143 | $-520 | $-395 | $-250 |
| Cash Flows From Financing Activities | |||||
| Common Stock Issued | 6,865 | 0 | N/A | 2,943 | N/A |
| Other Financing Activity | 0 | 0 | 4,030 | -12 | 90 |
| Financing Cash Flow | $6,865 | $0 | $4,030 | $2,931 | $90 |
| Beginning Cash Position | 1,602 | 1,602 | 2,000 | 2,001 | 2,000 |
| End Cash Position | 6,122 | 789 | 1,600 | 1,581 | 640 |
| Net Cash Flow | $4,520 | $-813 | $-390 | $-420 | $-1,360 |
| Free Cash Flow | |||||
| Operating Cash Flow | -2,092 | -671 | -3,900 | -2,956 | -1,200 |
| Capital Expenditure | N/A | N/A | N/A | -1 | N/A |
| Free Cash Flow | -2,092 | -671 | -3,900 | -2,958 | -1,200 |